Evidence map›Paper›PMID 37958877›Full record

ArticleInternational journal of molecular sciences2023

Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein.

Kalliopi Moschovou, Maria Antoniou, Eleni Chontzopoulou, Konstantinos D Papavasileiou, Georgia Melagraki, Antreas Afantitis, Thomas Mavromoustakos

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Viruses · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Quercetin: A Potential Polydynamic Drug.Molecules (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Kalliopi MoschovouDepartment of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Maria AntoniouDepartment of ChemoInformatics, NovaMechanics Ltd., 1046 Nicosia, Cyprus.
Eleni ChontzopoulouDepartment of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Konstantinos D PapavasileiouDepartment of ChemoInformatics, NovaMechanics Ltd., 1046 Nicosia, Cyprus.ORCID 0000-0002-2322-7422
Georgia MelagrakiDivision of Physical Sciences & Applications, Hellenic Military Academy, 16672 Vari, Greece.
Antreas AfantitisDepartment of ChemoInformatics, NovaMechanics Ltd., 1046 Nicosia, Cyprus.ORCID 0000-0002-0977-8180
Thomas MavromoustakosDepartment of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.ORCID 0000-0001-5309-992X
National and Kapodistrian University of Athens · GRNovaMechanics (Cyprus) · CYHellenic Military Academy · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this in silico study, we conducted an in-depth exploration of the potential of natural products and antihypertensive molecules that could serve as inhibitors targeting the key proteins of the SARS-CoV-2 virus: the main protease (Mpro) and the spike (S) protein. By utilizing Induced Fit Docking (IFD), we assessed the binding affinities of the molecules under study to these crucial viral components. To further comprehend the stability and molecular interactions of the "protein-ligand" complexes that derived from docking studies, we performed molecular dynamics (MD) simulations, shedding light on the molecular basis of potential drug candidates for COVID-19 treatment. Moreover, we employed Molecular Mechanics Generalized Born Surface Area (MM-GBSA) calculations on all "protein-ligand" complexes, underscoring the robust binding capabilities of rosmarinic acid, curcumin, and quercetin against Mpro, and salvianolic acid b, rosmarinic acid, and quercetin toward the S protein. Furthermore, in order to expand our search for potent inhibitors, we conducted a structure similarity analysis, using the Enalos Suite, based on the molecules that indicated the most favored results in the in silico studies. The Enalos Suite generated 115 structurally similar compounds to salvianolic acid, rosmarinic acid, and quercetin. These compounds underwent IFD calculations, leading to the identification of two salvianolic acid analogues that exhibited strong binding to all the examined binding sites in both proteins, showcasing their potential as multi-target inhibitors. These findings introduce exciting possibilities for the development of novel therapeutic agents aiming to effectively disrupt the SARS-CoV-2 virus lifecycle.

Indexed as

Biological ProductsCOVID-19AlkenesAntihypertensive AgentsAntiviral AgentsCOVID-19 Drug TreatmentHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationPeptide HydrolasesPolyphenolsProtease InhibitorsQuercetinRosmarinic AcidSARS-CoV-2AlkenesAntihypertensive AgentsAntiviral AgentsBiological ProductsLigandsPeptide HydrolasesPolyphenolsProtease InhibitorsQuercetinRosmarinic Acidsalvianolic acidSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2main proteasemolecular dockingmolecular dynamics simulationsSARS-CoV-2similarity searchspike protein

Identifiers

PMID37958877
PMCPMC10649947
OpenAlexW4388233072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.